Detailed Coverage

Acutaas Chemicals Sees Stellar Q1 FY27 with 59.1% Revenue Growth

Revenue from operations reached INR 329.7 crore, up 59.1% year-on-year.
PAT increased by 70.4% year-on-year to INR 74.9 crore.

Reader Takeaway: Strong margin expansion and new battery chemicals supply drive growth, offset by specialty chemical portfolio shift.

What just happened

Acutaas Chemicals Ltd has posted strong financial results for the first quarter of FY27. The company reported a revenue from operations of INR 329.7 crore, marking a significant 59.1% increase compared to the same period last year. Profit After Tax (PAT) also saw a substantial rise of 70.4%, reaching INR 74.9 crore.

Why this matters

These results indicate a strong operational performance and successful execution of the company's growth strategies. The significant revenue jump and improved profitability are positive signals for investors, suggesting enhanced market demand and efficient operations. The commencement of commercial supply for battery chemicals is a key milestone.

The backstory

The company's revenue growth was primarily driven by its Pharma Intermediates business, which saw a 76.5% year-on-year increase in revenue. In contrast, the Specialty Chemicals segment experienced a 10.6% decline, attributed to an intentional phase-out of commodity products to focus on higher-margin offerings.

What changes now

Acutaas Chemicals has successfully completed trial runs and begun commercial supply from its new battery chemicals plant. The Indichem plant in Korea for semiconductor chemicals is ahead of schedule, with construction expected to finish this quarter and commercialization next fiscal year. The company is confident in achieving 25% revenue growth for the full financial year.

Risks to watch

Management highlighted potential turbulence from geopolitical tensions, particularly in the Gulf, which could impact supply chains. However, raw material supply has been secured for now. The transition away from commodity products in Specialty Chemicals is expected to continue impacting that segment's revenue in the short term.

Peer comparison

(No direct peer comparison data available in the filing).

Context metrics (time-bound)

• Revenue from Operations: INR 329.7 crore (Q1 FY27), up 59.1% Y-o-Y.
• EBITDA: INR 113.1 crore (Q1 FY27), more than double the previous year.
• EBITDA Margin: 34.3% (Q1 FY27), up 973 basis points Y-o-Y.
• PAT: INR 74.9 crore (Q1 FY27), up 70.4% Y-o-Y.
• PAT Margin: 22.7% (Q1 FY27), up 151 basis points Y-o-Y.
• Pharma Intermediates Revenue: INR 292.7 crore, up 76.5% Y-o-Y.
• Specialty Chemicals Revenue: INR 37.0 crore, down 10.6% Y-o-Y.
• Battery Chemicals: Commercial supply commenced.
• Semiconductor Chemicals (Indichem, Korea): Construction ahead of schedule, commercialization from FY28.
• Capex (Q1 FY27): INR 56 crore.
• Net cash and cash equivalents: INR 314 crore (as of June 30, 2026).
• Working Capital: 99 days (Q1 FY27).

What to track next

Investors will be watching the scaling of the new battery chemicals and semiconductor chemicals projects. The company's ability to maintain margin expansion and achieve its guided 25% full-year revenue growth will be crucial. Monitoring the impact of the specialty chemicals portfolio shift is also important.